Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | MPO | P05164 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10596934 | 0.87 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL4328574 | 0.87 | HSD11B1 (0.55) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL5055312 | 0.87 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL30072318 | 0.87 | HSD11B1 (0.55) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL79787 | 0.87 | HSD11B1 (0.55) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL324893 | 0.87 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL21428 | 0.87 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| SCHEMBL2121770 | 0.87 | HSD11B1 (0.55) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL1219599 | 0.87 | HTR6 (1.00) | HTR6TSHRLMNAMPOCYP3A4 | |
| Dapsone SCHEMBL2203636 | 0.85 | HTR6 (0.94) | HTR6TSHRLMNAMPOCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873763-B2 | Solution of aromatic polyamide for manufacturing display element, optical element, illumination element or sensor element | AKRON POLYMER SYSTEMS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873763-B2 | Solution of aromatic polyamide for manufacturing display element, optical element, illumination element or sensor element | AKRON POLYMER SYSTEMS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20150099131-A1 | SOLUTION OF AROMATIC POLYAMIDE FOR MANUFACTURING DISPLAY ELEMENT, OPTICAL ELEMENT, ILLUMINATION ELEMENT OR SENSOR ELEMENT | AKRON POLYMER SYSTEMS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099131-A1 | SOLUTION OF AROMATIC POLYAMIDE FOR MANUFACTURING DISPLAY ELEMENT, OPTICAL ELEMENT, ILLUMINATION ELEMENT OR SENSOR ELEMENT | AKRON POLYMER SYSTEMS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-1641465-B1 | COMBINATIONS OF AN ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONIST AND A CORTICOSTEROID | THERAVANCE INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7582765-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7553971-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1446379-B1 | ARYL ANILINE BETA-2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-09-27 | — | — | US | disclosed |
| US-7125892-B2 | Aryl aniline β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |
| US-5100913-A | Venous antithrombotics | FOURNIER INDUSTRIE ET SANTE (FR) | 1992-03-31 | — | — | US | disclosed |
| EP-0451007-A1 | Sulphonylphenyl-beta-D-thioxylosides, process for their preparation and their use in therapy | FOURNIER INDUSTRIE ET SANTE (FR) | 1991-10-09 | — | — | EP | disclosed |
| EP-0354303-A1 | Amidines of diphenyl sulfones, their derivatives and their use | AMERICAN CYANAMID COMPANY (US) | 1990-02-14 | — | — | EP | disclosed |
| EP-0102476-B1 | METHOD OF MODULATING THE IMMUNE RESPONSE SYSTEM IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1986-11-05 | — | — | EP | disclosed |
| US-4532349-A | 2-Amino-4'(phenylsulfonyl) acetanilides | AMERICAN CYANAMID COMPANY (US) | 1985-07-30 | — | — | US | disclosed |
| EP-0102476-A1 | Method of modulating the immune response system in mammals | AMERICAN CYANAMID COMPANY (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4313872-A | MONDAZO AND DISAZO DYES | CASSELLA AKTIENGESELLSCHAFT (DE) | 1982-02-02 | — | — | US | disclosed |
| US-4118384-A | DIAZOTIZATION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225329-A1 | Aryl aniline beta2 adrenergic receptor agonists | ADRB2, ADRB3, ADRB1 | HTR6 243/4885TSHR 113/4885LMNA 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.